Back to search

Article

Vandetanib Drives Growth Arrest and Promotes Sensitivity to Imatinib in Hematologic Malignancies by Targeting Ephrin Type-B Receptor 4

2021-06-22

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>The oncogenic role of ephrin type-B receptor 4 (EphB4) has been reported in many types of tumors. However, little is known about its role in chronic myeloid leukemia (CML). <bold>Methods: </bold>A pool of clinically approved tyrosine kinase inhibitors (TKI) were screened for the antitumor activity using various hematologic cancer cell lines with different levels...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bdb6bae5-5e57-54ac-a8f9-796a51cdabb1
DOI
10.21203/rs.3.rs-633064/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Vandetanib Drives Growth Arrest and Promotes Sensitivity to Imatinib in Hematologic Malignancies by Targeting Ephrin Type-B Receptor 4DOI 10.21203/rs.3.rs-633064/v1
EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer TherapeuticsSemantic proximity
The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignanciesSemantic proximity
The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatmentSemantic proximity
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.Semantic proximity
Design and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer TherapySemantic proximity
<i>In silico</i> molecular target prediction unveils mebendazole as a potent MAPK14 inhibitorSemantic proximity
CXCR2 As a Novel Target for Overcoming Resistance to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia CellsSemantic proximity
Eph Receptors and Ephrins: Therapeutic OpportunitiesSemantic proximity
Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effectsSemantic proximity
Select a neighboring publication to make it the new centre.